Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
Location: United States, Massachusetts, Boston
Employees: 201-500
Total raised: $115M
Founded date: 2015
Investors 3
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| - | Vida Ventu... | vidaventur... |
| - | OrbiMed | orbimed.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.02.2019 | Series B | $93M | New Enterp... |
| 08.11.2017 | Series A | $22M | New Enterp... |
Mentions in press and media 10
| Date | Title | Description |
| 01.03.2019 | NEA is raising its biggest fund ever – – again | New Enterprise Associates, the 41-year-old venture firm with offices in Menlo Park; San Francisco; Boston; New York; Chevy Chase, Md.; and Washington, D.C., is raising its biggest fund ever, shows a new SEC filing that shows target of $3.6 ... |
| 26.02.2019 | Daily funding roundup - February 26th, 2019 | Elsa raised $7M; G2 Esports raised $17.3M; Tulip raised $18.4M; VAST Data raised $40M Attentive: Attentive’s augmented sales assistant integrates with Slack and aims to help teams keep up with their sales pipeline, has raised $1.2 million i... |
| 26.02.2019 | Term Sheet — Tuesday, February 26 | MO’ MONEY, MO’ PROBLEMS Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop PE funds produced another surge in investment value in 2018, capping the strongest five-year stretch in the indu... |
| 26.02.2019 | Oyster Point Raises $93M Series B | PRINCETON, N.J.--(BUSINESS WIRE)--Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies to treat Dry Eye Disease, today announced a $93 million Series B financi... |
| 26.02.2019 | Oyster Point Raises $93M in Series B Funding | Oyster Point Pharma, Inc., a Princeton, NJ-based clinical-stage pharmaceutical company with an initial focus on developing novel therapies to treat Dry Eye Disease, raised $93m in Series B financing. The round was co-led by Invus Opportunit... |
| 26.02.2019 | NEA Joins $93M Series B for Oyster Point | PRINCETON, N.J.--(BUSINESS WIRE)--Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies to treat Dry Eye Disease, today announced a $93 million Series B financi... |
| 09.11.2017 | Term Sheet — Thursday, November 9 | CAN TECH STARTUPS SAVE PRINT? Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop This illustrates an interesting trend I’ve noticed recently. While traditional media companies are pivoting to vi... |
| 08.11.2017 | NEA Leads $22M Series A for Oyster Point Pharmaceuticals | SAN FRANCISCO--(BUSINESS WIRE)--Oyster Point Pharmaceuticals Inc., which is developing novel therapies for dry eye and other diseases of the ocular surface, today announced the completion of a $22 million Series A financing led by New Enter... |
| 08.11.2017 | Oyster Point Pharmaceuticals Nets $22M Series A | SAN FRANCISCO, CA, Oyster Point Pharmaceuticals announced the completion of a $22 million Series A financing led by New Enterprise Associates and Versant Ventures. >> Click here for more funding data on Oyster Point Pharmaceuticals... |
| 07.11.2017 | Oyster Point Pharmaceuticals Completes $22M Series A Financing | Oyster Point Pharmaceuticals Inc., a San Francisco, CA-based developer of novel therapies for dry eye and other diseases of the ocular surface, completed a $22m Series A financing. The round was led by New Enterprise Associates and Versant ... |